B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer
Drug Resistance Updates · 2025
DOI: 10.1016/j.drup.2025.101207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Yong Ju und 20 weiteren Autor:innen. Beteiligte Einrichtung: California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, …. Hauptthemen laut MEDLINE: B7 Antigens, Extracellular Vesicles, Prostatic Neoplasms, Castration-Resistant, Biomarkers, Tumor. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, US Department of Defense, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: B7-H3 is a promising target for cancer therapy, notably in prostate cancer (PCa), particularly in metastatic, castration-resistant PCa (mCRPC). With the development of B7-H3-targeted therapies, there is a need for a rapid, reliable, and cost-effective method to detect and monitor B7-H3 expression. Leveraging their abundance and stability, we developed a liquid biopsy assay using extracellular vesicles (EVs) for this purpose. METHODS: B7-H3+ EVs were isolated using a B7-H3 antibody-mediated, click chemistry-based enrichment method. Antibodies were conjugated to methyltetrazine-grafted microbeads. EVs were isolated from 100 µL of plasma from metastatic, castration-sensitive PCa (mCSPC) (n = 43) and mCRPC (n = 103) patients and quantified using RT-qPCR of ACTB. Measurements were compared with the patient's disease status over time. RESULTS: The assay detected higher B7-H3+ EVs in mCRPC than mCSPC and increased when mCSPC transitioned to mCRPC. Elevated B7-H3+ EVs were associated with lower overall survival (Hazard ratio (HR) 2.19, p = 0.01). In patients with serial plasma samples, B7-H3+ EV levels reflected treatment response and disease progression. CONCLUSIONS: This B7-H3+ EV assay represents a significant advancement in utilizing tumor-derived EVs for a non-invasive, quantitative, and consistent real-time measurement of B7-H3. This assay warrants further development as a companion diagnostic for B7-H3 targeted therapies in PCa and other conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: YJ…
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: Joshua.Watson@csmns.org.
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: jasmine.ji…
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: YYen@mednet.ucla.edu.
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: lilit.gevorkian2@cshs.org.
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: zijing.chen@cshs.org.
Förderung
- NCI NIH HHS
- US Department of Defense
- National Institutes of Health
- National Institutes of Health National Cancer Institute
Zitieren
APA
Ju, Y., Watson, J., Wang, J. J., Yen, Y. T., Gevorkian, L., Chen, Z., Tu, K. H., Salumbides, B., Phung, A., Zhao, C., Kim, H., Ji, Y. R., Zhang, R. Y., Lee, J., Gong, J., Scher, K., You, S., Chen, J. F., Tseng, H. R., …, & Posadas, E. M. (2025). B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101207
Vancouver
Ju Y, Watson J, Wang JJ, Yen YT, Gevorkian L, Chen Z, et al. B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101207
BibTeX
@article{Ju2025,
author = {Ju, Yong and Watson, Joshua and Wang, Jasmine J and Yen, Ying-Tzu and Gevorkian, Lilit and Chen, Zijing and Tu, Kai Han and Salumbides, Brenda and Phung, Aaron and Zhao, Chen and Kim, Hyoyong and Ji, You-Ren and Zhang, Ryan Y and Lee, Junseok and Gong, Jun and Scher, Kevin and You, Sungyong and Chen, Jie-Fu and Tseng, Hsian-Rong and Zhu, Yazhen and Posadas, Edwin M},
title = {B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer},
journal = {Drug Resistance Updates},
year = {2025},
doi = {10.1016/j.drup.2025.101207}
}
EUVIMED